Last updated: 18 July 2019 at 8:59pm EST

R. Douglas Norby Net Worth




The estimated Net Worth of R Douglas Norby is at least $11.6 Million dollars as of 9 May 2018. Mr. Norby owns over 9,000 units of Krystal Biotech Inc stock worth over $1,789,110 and over the last 21 years he sold KRYS stock worth over $9,775,318. In addition, he makes $61,500 as Lead Independent Director at Krystal Biotech Inc.

Mr. Norby KRYS stock SEC Form 4 insiders trading

R has made over 17 trades of the Krystal Biotech Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of KRYS stock worth $93,780 on 9 May 2018.

The largest trade he's ever made was selling 45,442 units of Krystal Biotech Inc stock on 11 December 2015 worth over $8,529,918. On average, R trades about 7,094 units every 78 days since 2003. As of 9 May 2018 he still owns at least 9,000 units of Krystal Biotech Inc stock.

You can see the complete history of Mr. Norby stock trades at the bottom of the page.





R. Douglas Norby biography

R. Douglas Norby serves as Lead Independent Director of the Company. Mr. Norby is a director of SymBio Pharmaceuticals, Ltd., a Japanese pharmaceutical company listed on the Tokyo Exchange, and previously served as lead independent director on the board of directors of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), where he was a board member from September 1999 to September 2019. Mr. Norby has held positions of responsibility at many companies, including serving as Senior Vice President and Chief Financial Officer of Tessera, Inc., a provider of intellectual property for advanced semiconductor packaging; and as Senior Vice President and Chief Financial Officer of Zambeel, Inc., a data storage systems company. Mr. Norby has also served as Senior Vice President and Chief Financial Officer of Novalux, Inc., a manufacturer of lasers for optical networks; as Executive Vice President and Chief Financial Officer of LSI Logic Corporation, a semiconductor company which was acquired by Avago Technologies in 2013; as Senior Vice President and Chief Financial Officer of Mentor Graphics Corporation, a software company; and as President and Chief Operating Officer at Lucasfilm, Ltd., an entertainment company. His pharmaceutical experience includes serving as President of Pharmetrix Corporation, a drug delivery company, as Senior Vice President and Chief Financial Officer of Syntex Corporation, a pharmaceutical company, which was later acquired by Roche Holding Ltd. Mr. Norby received a bachelor’s degree in Economics from Harvard University and an MBA from Harvard Business School.

What is the salary of R Norby?

As the Lead Independent Director of Krystal Biotech Inc, the total compensation of R Norby at Krystal Biotech Inc is $61,500. There are 8 executives at Krystal Biotech Inc getting paid more, with Krish S. Krishnan M.B.A., M.S. having the highest compensation of $1,008,932.



What's R Norby's mailing address?

R's mailing address filed with the SEC is 20400 STEVENS CREEK BOULEVARD, SUITE 370, , CUPERTINO, CA, 95014.

Insiders trading at Krystal Biotech Inc

Over the last 7 years, insiders at Krystal Biotech Inc have traded over $166,816,526 worth of Krystal Biotech Inc stock and bought 536,800 units worth $5,949,380 . The most active insiders traders include Daniel Janney, Dino A Rossi, and Krish S Krishnan. On average, Krystal Biotech Inc executives and independent directors trade stock every 40 days with the average trade being worth of $8,043,043. The most recent stock trade was executed by Suma Krishnan on 11 June 2024, trading 50,000 units of KRYS stock currently worth $8,788,000.



What does Krystal Biotech Inc do?

krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)



What does Krystal Biotech Inc's logo look like?

Krystal Biotech Inc logo

Complete history of Mr. Norby stock trades at Alexion Pharmaceuticals, MagnaChip Semiconductor Corp, and Krystal Biotech Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
9 May 2018 R Douglas Norby
Director
Buy 9,000 $10.42 $93,780
9 May 2018
9,000
23 Sep 2016 R Douglas Norby
Director
Option 15,500 $129.94 $2,014,070
23 Sep 2016
2,876
23 Sep 2016 R Douglas Norby
Director
Option 15,500 $129.94 $2,014,070
23 Sep 2016
2,876
11 Dec 2015 R Douglas Norby
Director
Sale 45,442 $187.71 $8,529,918
11 Dec 2015
32,481
22 May 2013 R Douglas Norby
Director
Option 40,000 $13.89 $555,600
22 May 2013
96,144
10 Dec 2012 R Douglas Norby
Director
Option 22,000 $6.81 $149,820
10 Dec 2012
60,673
8 Mar 2012 R Douglas Norby
Director
Option 30,000 $8.18 $245,400
8 Mar 2012
59,043
3 Feb 2012 R Douglas Norby
Director
Option 3,115 $78.88 $245,711
3 Feb 2012
30,743
27 Oct 2011 R Douglas Norby
Director
Option 45,000 $5.34 $240,300
27 Oct 2011
53,748
14 Feb 2011 R Douglas Norby
Director
Option 23,000 $7.43 $170,890
14 Feb 2011
36,814
28 Jan 2010 R Douglas Norby
Director
Option 3,965 $22.90 $90,799
28 Jan 2010
15,054
3 Nov 2009 R Douglas Norby
Director
Option 15,000 $7.79 $116,850
3 Nov 2009
26,089
24 Aug 2009 R Douglas Norby
Director
Option 17,000 $40.46 $687,820
24 Aug 2009
28,089
4 Aug 2009 R Douglas Norby
Director
Option 2,000 $42.06 $84,120
4 Aug 2009
13,089
19 Jun 2009 R Douglas Norby
Director
Option 20,000 $32.25 $645,000
19 Jun 2009
31,089
16 Mar 2009 R Douglas Norby
Director
Sale 32,000 $35.07 $1,122,240
16 Mar 2009
11,089
20 Feb 2008 R Douglas Norby
Director
Sale 2,000 $61.58 $123,160
20 Feb 2008
4,000


Krystal Biotech Inc executives and stock owners

Krystal Biotech Inc executives and other stock owners filed with the SEC include: